Survey

Last month's survey results:

With the evolution of the medical home and ACO models of healthcare delivery, what do you see as the most essential means by which pharmacy departments can support the success of such models?

a) More active direct patient outreach, education and consultation. 40%

b) Enhanced provider education and drug info support. 9%

c) Improved ability to deliver more timely and actionable patient-specific drug alerts to PCPs/care managers. 18%

d) Enhanced mechanisms to monitor and improve patient compliance. 23%

d) More advanced analytics to better risk stratify patients for intervention need. 5%

e) More timely and robust reporting to measure pharmacy-specific quality performance metrics. 5%

With the recent announcement of Medco's acquisition by Express Scripts, potentially bringing 2 of the nation's largest PBMs together, what do you see as the most significant implications of such consolidation for the industry:

a) Enhanced competition within the industry, inevitably translating to even lower drug costs for PBM payer clients.

b) Unfair advantages for Express Scripts based upon its size, thus reducing competition and potentially increasing long-term costs for payers.

c) Increased pressures on retail pharmacies forcing more pharmacies out of business.

d) Increased quality of PBM clinical, analytic and administrative services across the industry, as other PBMs strive to stay competitive.

e) Minimal, if any, impact.

Digital Edition

Study provides first evidence-based colchicine dosing recommendations

To confirm your e-newsletter subscription, click here.

To ensure future delivery of email newsletters from Formulary, please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff

Linaclotide reduces symptoms for patients with chronic constipation, studies show

FDA Safety Alert: Abnormal heart rhythms associated with high doses of citalopram hydrobromide

FDA has notified healthcare professionals and patients that the antidepressant citalopram hydrobromide (Celexa, Forest Laboratories) should no longer be used at doses greater than 40 mg per day because it can cause abnormal changes in the electrical activity of the heart. Read full article.

FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer

FDA approved crizotinib (Xalkori, Pfizer) the first and only therapy specifically for patients with locally advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Read full article.

FDA approves tapentadol ER for management of moderate-to-severe chronic pain

FDA has approved tapentadol extended-release tablets (Nucynta ER, Janssen Pharmaceuticals), an oral analgesic taken twice daily, for the management of moderate-to-severe chronic pain in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Read full article.

FDA approves Botox to treat a form of urinary incontinence

FDA has approved onabotulinumtoxinA (Botox, Allergan) for injection for the treatment of urinary incontinence resulting from detrusor overactivity associated with a neurologic condition (eg, spinal cord injury [SCI], multiple sclerosis [MS]) in adults who have an inadequate response to or are intolerant of an anticholinergic medication. Read full article.

FDA approves icatibant to treat acute attacks of hereditary angioedema

FDA has approved icatibant (Firazyr, Shire Human Genetic Therapies) injection for the treatment of acute attacks of hereditary angioedema (HAE) in patients 18 years of age and older. Read full article.